الفهرس 
EndometriosisOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Endometriosis is defined as implantation and growth of endometrial tissue in sites other than the endometrium. It manifests itself with dysmenorrhea, chronic pelvic pain, pelvic inflammatory reaction and infertility. It is an estrogen-dependent inflammatory disease that affects 5 to 10% of women of reproductive age in the United States (Giudice and Kao, 2004).
Among the most consistent relations in the literature is the inverse association between endometriosis and a woman’s current body mass index (BMI) (Hediger et al., 2005).
Nesfatin-1 is a recently identified peptide. It is identified as a satiety molecule that decreases food intake in a dose-dependent manner (Oh-I et al., 2006). It also has effects on glucose and energy metabolism, obesity and probably gonadal functions (Deniz et al., 2012) and has anti-inflammatory and anti-apoptotic effects (Tang et al., 2012).
This is a cross sectional case-control study that was conducted in Ain Shams University Maternity Hospital, during the period from December 2014 till October 2015 to assess the association between endometriosis, obesity and nesfatin-1.
Sixty patients were included in this study divided into 2 groups with 30 patients each: (Control group) and (Endometriosis group).
The study showed that patients with endometriosis had lower BMI than controls (25.4 ± 1.9 kg/m2 vs. 29.4 ± 2.9 kg/m2, p <0.001).
Also showed that the most common laparoscopic finding in the control group to be polycystic ovaries (43.34%) and that the most prevalent endometriosis stage according to the revised ASRM scoring system in the endometriosis group was mainly stage III (40 %) and stage IV (27%).
More women presented with primary infertility than with secondary infertility (58.50% 1ry vs. 41.50% 2ry of total 53 infertile women).
Endometriosis patients were nullipara (66.7%), statistically significantly more than the control group with only (43.3%) nulliparous. And dysmenorrhea was more common among endometriosis patients group (27 patients (90%) vs. 11 women of controls (36.7%), p<0.001).
The study showed lower serum nesfatin-1 levels in patients with endometriosis than controls, a finding that persisted after adjustment for age and BMI, which indicates a possible role for nesfatin-1 in the etiopathogenesis of endometriosis.
Also, this study presented an excellent discriminatory cut-off value of ≤310 pg/ml nesfatin-1 serum level between endometriotic and non-endometriotic patients.
And demonstrated a moderate positive correlation between serum nesfatin-1 levels and BMI.